Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ted Snelgrove, Bernard Sixt, Nicolas Pasqual, Keith Brownlie

Premium

Cellscape has named Ted Snelgrove as its new CEO.

Snelgrove joins the prenatal genetic testing firm from Crescendo Bioscience, where he served as chief commercial officer. He also worked previously at Genomic Health, where he was vice president of sales and marketing.


Bernard Sixt has joined ImmunID as its new president and CEO.

Sixt was CEO of Agendia from 2003 to 201. He takes over the CEO position from ImmunID cofounder Nicolas Pasqual, who will continue on as the company's chief scientific officer.


Cancer Genetics has named Keith Brownlie to its board of directors and to its audit committee. Brownlie has served as the audit partner for a number of life sciences companies, including Epicet and Rxi Pharmaceuticals.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.